Rift Valley fever

Last updated
Rift Valley fever
Rift Valley fever tissue.jpg
TEM micrograph of tissue infected with Rift Valley fever virus
Specialty Infectious diseases, veterinary medicine   OOjs UI icon edit-ltr-progressive.svg
Symptoms Fever, muscle pains, headaches [1]
Complications Loss of sight, confusion, bleeding, liver problems [1]
DurationUp to a week [1]
Causes Phlebovirus spread by an infected animal or mosquito [1]
Diagnostic method Finding antibodies or the virus in the blood [1]
PreventionVaccinating animals against the disease, decreasing mosquito bites [1]
Treatment Supportive care [1]
FrequencyOutbreaks in Africa and Arabia [1]

Rift Valley fever (RVF) is a viral disease of humans and livestock that can cause mild to severe symptoms. The mild symptoms may include: fever, muscle pains, and headaches which often last for up to a week. The severe symptoms may include: loss of sight beginning three weeks after the infection, infections of the brain causing severe headaches and confusion, and bleeding together with liver problems which may occur within the first few days. Those who have bleeding have a chance of death as high as 50%. [1]

Contents

The disease is caused by the RVF virus. It is spread by either touching infected animal blood, breathing in the air around an infected animal being butchered, drinking raw milk from an infected animal, or the bite of infected mosquitoes. Animals such as cows, sheep, goats, and camels may be affected. In these animals it is spread mostly by mosquitoes. [1] It does not appear that one person can infect another person. The disease is diagnosed by finding antibodies against the virus or the virus itself in the blood. [1]

Prevention of the disease in humans is accomplished by vaccinating animals against the disease. This must be done before an outbreak occurs because if it is done during an outbreak it may worsen the situation. Stopping the movement of animals during an outbreak may also be useful, as may decreasing mosquito numbers and avoiding their bites. There is a human vaccine; however, as of 2010 it is not widely available. There is no specific treatment and medical efforts are supportive. [1]

Outbreaks of the disease have only occurred in Africa and Arabia. Outbreaks usually occur during periods of increased rain which increase the number of mosquitoes. [1] The disease was first reported among livestock in Rift Valley of Kenya in the early 1900s, [2] and the virus was first isolated in 1931. [1]

Signs and symptoms

In humans, the virus can cause several syndromes. Usually, they have either no symptoms or only a mild illness with fever, headache, muscle pains, and liver abnormalities. In a small percentage of cases (< 2%), the illness can progress to hemorrhagic fever syndrome, meningoencephalitis (inflammation of the brain and tissues lining the brain), or affect the eye. Patients who become ill usually experience fever, generalised weakness, back pain, dizziness, and weight loss at the onset of the illness. Typically, people recover within two to seven days after onset. About 1% of people with the disease die of it. In livestock, the fatality level is significantly higher. Pregnant livestock infected with RVF abort virtually 100% of foetuses. An epizootic (animal disease epidemic) of RVF is usually first indicated by a wave of unexplained abortions.[ citation needed ]

Other signs in livestock include vomiting and diarrhea, respiratory disease, fever, lethargy, anorexia and sudden death in young animals. [3]

Cause

Virology

Rift Valley fever phlebovirus
Viruses-08-00174-g001.png
Phlebovirus virion and genome
Virus classification OOjs UI icon edit-ltr.svg
(unranked): Virus
Realm: Riboviria
Kingdom: Orthornavirae
Phylum: Negarnaviricota
Class: Ellioviricetes
Order: Bunyavirales
Family: Phenuiviridae
Genus: Phlebovirus
Species:
Rift Valley fever phlebovirus

The virus belongs to the Bunyavirales order. This is an order of enveloped negative single stranded RNA viruses. All Bunyaviruses have an outer lipid envelope with two glycoproteins—G(N) and G(C)—required for cell entry. They deliver their genome into the host-cell cytoplasm by fusing their envelope with an endosomal membrane.[ citation needed ]

The virus' G(C) protein has a class II membrane fusion protein architecture similar to that found in flaviviruses and alphaviruses. [4] This structural similarity suggests that there may be a common origin for these viral families.[ citation needed ]

The virus' 11.5 kb tripartite genome is composed of single-stranded RNA. As a Phlebovirus, it has an ambisense genome. Its L and M segments are negative-sense, but its S segment is ambisense. [5] These three genome segments code for six major proteins: L protein (viral polymerase), the two glycoproteins G(N) and G(C), the nucleocapsid N protein, and the nonstructural NSs and NSm proteins. [6]

Transmission

The virus is transmitted through mosquito vectors, as well as through contact with the tissue of infected animals. Two species— Culex tritaeniorhynchus and Aedes vexans —are known to transmit the virus. [7] Other potential vectors include Aedes caspius , Aedes mcintosh , Aedes ochraceus, Culex pipiens , Culex antennatus , Culex perexiguus , Culex zombaensis and Culex quinquefasciatus . [8] [9] [10] Contact with infected tissue is considered to be the main source of human infections. [11] The virus has been isolated from two bat species: the Peter's epauletted fruit bat (Micropteropus pusillus) and the aba roundleaf bat (Hipposideros abae), which are believed to be reservoirs for the virus. [12]

Pathogenesis

Although many components of the RVFV's RNA play an important role in the virus' pathology, the nonstructural protein encoded on the S segment (NSs) is the only component that has been found to directly affect the host. NSs is hostile and combative against the host interferon (IFNs) antiviral response. [13] IFNs are essential in order for the immune system to fight off viral infections in a host. [14] This inhibitory mechanism is believed to be due to a number of reasons, the first being, competitive inhibition of the formation of the transcription factor. [13] On this transcription factor, NSs interacts with and binds to a subunit that is needed for RNA polymerase I and II. [13] [15] This interaction cause competitive inhibition with another transcription factor component and prevents the assembly process of the transcription factor complex, which results in the suppression of the host antiviral response. [13] [15] Transcription suppression is believed to be another mechanism of this inhibitory process. [13] This occurs when an area of NSs interacts with and binds to the host's protein, SAP30 and forms a complex. [13] [15] This complex causes histone acetylation to regress, which is needed for transcriptional activation of the IFN promoter. [15] This causes IFN expression to be obstructed. Lastly, NSs has also been known to affect regular activity of double-stranded RNA-dependent protein kinase R. This protein is involved in cellular antiviral responses in the host. When RVFV is able to enter the host's DNA, NSs forms a filamentous structure in the nucleus. This allows the virus to interact with specific areas of the host's DNA that relates to segregation defects and induction of chromosome continuity. This increases host infectivity and decreases the host's antiviral response. [13]

Diagnosis

Diagnosis relies on viral isolation from tissues, or serological testing with an ELISA. [3] Other methods of diagnosis include Nucleic Acid Testing (NAT), cell culture, and IgM antibody assays. [16] As of September 2016, the Kenya Medical Research Institute (KEMRI) has developed a product called Immunoline, designed to diagnose the disease in humans much faster than in previous methods. [17]

Prevention

A person's chances of becoming infected can be reduced by taking measures to decrease contact with blood, body fluids, or tissues of infected animals and protection against mosquitoes and other bloodsucking insects. Use of mosquito repellents and bed nets are two effective methods. For persons working with animals in RVF-endemic areas, wearing protective equipment to avoid any exposure to blood or tissues of animals that may potentially be infected is an important protective measure. [18] Potentially, establishing environmental monitoring and case surveillance systems may aid in the prediction and control of future RVF outbreaks. [18]

No vaccines are currently available for humans. [18] [1] While a vaccines have been developed for humans, it has only been used experimentally for scientific personnel in high-risk environments. [1] Trials of a number of vaccines, such as NDBR-103 and TSI-GSD 200, are ongoing. [19] Different types of vaccines for veterinary use are available. The killed vaccines are not practical in routine animal field vaccination because of the need of multiple injections. Live vaccines require a single injection but are known to cause birth defects and abortions in sheep and induce only low-level protection in cattle. The live-attenuated vaccine, MP-12, has demonstrated promising results in laboratory trials in domesticated animals, but more research is needed before the vaccine can be used in the field. The live-attenuated clone 13 vaccine was recently registered and used in South Africa. Alternative vaccines using molecular recombinant constructs are in development and show promising results. [18]

A vaccine has been conditionally approved for use in animals in the US. [20] It has been shown that knockout of the NSs and NSm nonstructural proteins of this virus produces an effective vaccine in sheep as well. [21]

Epidemiology

Distribution of Rift Valley fever in Africa: Blue, countries with endemic disease and substantial outbreaks of RVF; green, countries known to have some cases, periodic isolation of virus, or serologic evidence of RVF Rift valley fever distribution.jpg
Distribution of Rift Valley fever in Africa: Blue, countries with endemic disease and substantial outbreaks of RVF; green, countries known to have some cases, periodic isolation of virus, or serologic evidence of RVF

RVF outbreaks occur across sub-Saharan Africa, with outbreaks occurring elsewhere infrequently. Outbreaks of this disease usually correspond with the warm phases of the EI Niño/Southern Oscillation. During this time there is an increase in rainfall, flooding and greenness of vegetation index, which leads to an increase in mosquito vectors. [22] RVFV can be transmitted vertically in mosquitos, meaning that the virus can be passed from the mother to her offspring. During dry conditions, the virus can remain viable for a number of years in the egg. Mosquitos lay their eggs in water, where they eventually hatch. As water is essential for mosquito eggs to hatch, rainfall and flooding cause an increase in the mosquito population and an increased potential for the virus. [23]

The first documented outbreak was identified in Kenya in 1931, in sheep, cattle and humans; [24] another severe outbreak in the country in 1950–1951 involved 100,000 deaths in livestock and an unrecorded number of humans with fever. [25] An outbreak occurred in South Africa in 1974–1976, with more than 500,000 infected animals and the first deaths in humans. [26] [27] In Egypt in 1977–78, an estimated 200,000 people were infected and there were at least 594 deaths. [28] [29] In Kenya in 1998, the virus killed more than 400 people.[ citation needed ] Since then, there have been outbreaks in Saudi Arabia and Yemen (2000),[ citation needed ] East Africa (2006–2007), [30] Sudan (2007), [31] South Africa (2010), [32] [33] Uganda (2016), [34] Kenya (2018), [35] and Mayotte (2018–2019). [36] 2020–2021 in Kenya, [37] in 2022 an outbreak is ongoing in Burundi.

Biological weapon

Rift Valley fever was one of more than a dozen agents that the United States researched as potential biological weapons before the nation suspended its biological weapons program in 1969. [38] [39]

Research

The disease is one of several identified by WHO as a likely cause of a future epidemic in a new plan developed after the Ebola epidemic for urgent research and development toward new diagnostic tests, vaccines and medicines. [40] [41]

See also

Related Research Articles

<span class="mw-page-title-main">Yellow fever</span> Viral disease common in tropical Africa and South America

Yellow fever is a viral disease of typically short duration. In most cases, symptoms include fever, chills, loss of appetite, nausea, muscle pains – particularly in the back – and headaches. Symptoms typically improve within five days. In about 15% of people, within a day of improving the fever comes back, abdominal pain occurs, and liver damage begins causing yellow skin. If this occurs, the risk of bleeding and kidney problems is increased.

<span class="mw-page-title-main">West Nile fever</span> Human disease caused by West Nile virus infection

West Nile fever is an infection by the West Nile virus, which is typically spread by mosquitoes. In about 80% of infections people have few or no symptoms. About 20% of people develop a fever, headache, vomiting, or a rash. In less than 1% of people, encephalitis or meningitis occurs, with associated neck stiffness, confusion, or seizures. Recovery may take weeks to months. The risk of death among those in whom the nervous system is affected is about 10 percent.

<span class="mw-page-title-main">Dengue fever</span> Tropical disease caused by the dengue virus, transmitted by mosquito

Dengue fever is a mosquito-borne tropical disease caused by the dengue virus. Symptoms typically begin 3 to 14 days after infection. These may include a high fever, headache, vomiting, muscle and joint pains, and a characteristic skin itching and skin rash. Recovery generally takes two to seven days. In a small proportion of cases, the disease develops into a more severe dengue hemorrhagic fever, resulting in bleeding, low levels of blood platelets and blood plasma leakage, or into dengue shock syndrome, where dangerously low blood pressure occurs.

<span class="mw-page-title-main">Chikungunya</span> Infection caused by the Chikungunya virus

Chikungunya is an infection caused by the Chikungunya virus (CHIKV). The disease was first identified in 1952 in Tanzania and named based on the Kimakonde words for "to become contorted". Symptoms include fever and joint pain. These typically occur two to twelve days after exposure. Other symptoms may include headache, muscle pain, joint swelling, and a rash. Symptoms usually improve within a week; however, occasionally the joint pain may last for months or years. The risk of death is around 1 in 1,000. The very young, old, and those with other health problems are at risk of more severe disease.

<span class="mw-page-title-main">Arbovirus</span> Common name for several species of virus

Arbovirus is an informal name for any virus that is transmitted by arthropod vectors. The term arbovirus is a portmanteau word. Tibovirus is sometimes used to more specifically describe viruses transmitted by ticks, a superorder within the arthropods. Arboviruses can affect both animals and plants. In humans, symptoms of arbovirus infection generally occur 3–15 days after exposure to the virus and last three or four days. The most common clinical features of infection are fever, headache, and malaise, but encephalitis and viral hemorrhagic fever may also occur.

Bolivian hemorrhagic fever (BHF), also known as black typhus or Ordog Fever, is a hemorrhagic fever and zoonotic infectious disease originating in Bolivia after infection by Machupo mammarenavirus.

<i>Bunyavirales</i> Order of RNA viruses

Bunyavirales is an order of segmented negative-strand RNA viruses with mainly tripartite genomes. Member viruses infect arthropods, plants, protozoans, and vertebrates. It is the only order in the class Ellioviricetes. The name Bunyavirales derives from Bunyamwera, where the original type species Bunyamwera orthobunyavirus was first discovered. Ellioviricetes is named in honor of late virologist Richard M. Elliott for his early work on bunyaviruses.

<span class="mw-page-title-main">Viral hemorrhagic fever</span> Type of illnesses

Viral hemorrhagic fevers (VHFs) are a diverse group of animal and human illnesses. VHFs may be caused by five distinct families of RNA viruses: the families Filoviridae, Flaviviridae, Rhabdoviridae, and several member families of the Bunyavirales order such as Arenaviridae, and Hantaviridae. All types of VHF are characterized by fever and bleeding disorders and all can progress to high fever, shock and death in many cases. Some of the VHF agents cause relatively mild illnesses, such as the Scandinavian nephropathia epidemica, while others, such as Ebola virus, can cause severe, life-threatening disease.

<i>Thogotovirus</i> Genus of viruses

Thogotovirus is a genus of enveloped RNA viruses, one of seven genera in the virus family Orthomyxoviridae. Their single-stranded, negative-sense RNA genome has six or seven segments. Thogotoviruses are distinguished from most other orthomyxoviruses by being arboviruses – viruses that are transmitted by arthropods, in this case usually ticks. Thogotoviruses can replicate in both tick cells and vertebrate cells; one subtype has also been isolated from mosquitoes. A consequence of being transmitted by blood-sucking vectors is that the virus must spread systemically in the vertebrate host – unlike influenza viruses, which are transmitted by respiratory droplets and are usually confined to the respiratory system.

A reverse zoonosis, also known as a zooanthroponosis or anthroponosis, is a pathogen reservoired in humans that is capable of being transmitted to non-human animals.

Clarence James Peters, Jr is a physician, field virologist and former U.S. Army colonel. He is noted for his efforts in trying to stem epidemics of exotic infectious diseases such as the Ebola virus, Hanta virus and Rift Valley fever (RVF). He is an eminent authority on the virology, pathogenesis and epidemiology of hemorrhagic fever viruses.

<span class="mw-page-title-main">Mosquito-borne disease</span> Diseases caused by bacteria, viruses or parasites transmitted by mosquitoes

Mosquito-borne diseases or mosquito-borne illnesses are diseases caused by bacteria, viruses or parasites transmitted by mosquitoes. Nearly 700 million people get a mosquito-borne illness each year, resulting in over 725,000 deaths.

<i>Zika virus</i> Species of flavivirus

Zika virus is a member of the virus family Flaviviridae. It is spread by daytime-active Aedes mosquitoes, such as A. aegypti and A. albopictus. Its name comes from the Ziika Forest of Uganda, where the virus was first isolated in 1947. Zika virus shares a genus with the dengue, yellow fever, Japanese encephalitis, and West Nile viruses. Since the 1950s, it has been known to occur within a narrow equatorial belt from Africa to Asia. From 2007 to 2016, the virus spread eastward, across the Pacific Ocean to the Americas, leading to the 2015–2016 Zika virus epidemic.

Batai orthobunyavirus (BATV) is a RNA virus belonging to order Bunyavirales, genus Orthobunyavirus.

Cache Valley orthobunyavirus (CVV) is a member of the order Bunyavirales, genus Orthobunyavirus, and serogroup Bunyamwera, which was first isolated in 1956 from Culiseta inornata mosquitos collected in Utah's Cache Valley. CVV is an enveloped arbovirus, nominally 80–120 nm in diameter, whose genome is composed of three single-stranded, negative-sense RNA segments. The large segment of related bunyaviruses is approximately 6800 bases in length and encodes a probable viral polymerase. The middle CVV segment has a 4463-nucleotide sequence and the smallest segment encodes for the nucleocapsid, and a second non-structural protein. CVV has been known to cause outbreaks of spontaneous abortion and congenital malformations in ruminants such as sheep and cattle. CVV rarely infects humans, but when they are infected it has caused encephalitis and multiorgan failure.

Jamestown Canyon encephalitis is an infectious disease caused by the Jamestown Canyon virus, an orthobunyavirus of the California serogroup. It is mainly spread during the summer by different mosquito species in the United States and Canada.

<i>West Nile virus</i> Species of flavivirus causing West Nile fever

West Nile virus (WNV) is a single-stranded RNA virus that causes West Nile fever. It is a member of the family Flaviviridae, from the genus Flavivirus, which also contains the Zika virus, dengue virus, and yellow fever virus. The virus is primarily transmitted by mosquitoes, mostly species of Culex. The primary hosts of WNV are birds, so that the virus remains within a "bird–mosquito–bird" transmission cycle. The virus is genetically related to the Japanese encephalitis family of viruses. Humans and horses both exhibit disease symptoms from the virus, and symptoms rarely occur in other animals.

<span class="mw-page-title-main">2006–2007 East Africa Rift Valley fever outbreak</span> East Africa fever outbreak

East Africa had a regional outbreak of Rift Valley fever in late 2006 that affected Kenya, Somalia, and Tanzania. During outbreak, 1062 people were infected with Rift Valley fever and 394 people died between December 2006 and December 2007. Rift Valley fever (RVF) is caused by a phlebovirus in the Bunyavirales order which is transmitted by mosquito bite and contact with infected animal blood; it mainly infects livestock that come into infectious contact with a viral reservoir but human beings can also be infected. The outbreak began after a heavy El Niño rain season across East Africa left greater than usual breeding ground for Aedes aegypti mosquitos, with particularly heavy rainfall over eastern Kenya, central Tanzania, and southern Somalia. While most people infected with the virus experience a relatively mild, flu-like illness without hospitalization, around 8% will develop a severe illness that can include eye disease, encephalitis, hemorrhagic fever and death. During this outbreak, of the 1,062 hospitalized, laboratory-confirmed RVF cases assays, 37% died.

<i>Sepik virus</i> Mosquito transmitted virus endemic to Papua New Guinea

Sepik virus (SEPV) is an arthropod-borne virus (arbovirus) of the genus Flavivirus and family Flaviviridae. Flaviviridae is one of the most well characterized viral families, as it contains many well-known viruses that cause diseases that have become very prevalent in the world, like Dengue virus. The genus Flavivirus is one of the largest viral genera and encompasses over 50 viral species, including tick and mosquito borne viruses like Yellow fever virus and West Nile virus. Sepik virus is much less well known and has not been as well-classified as other viruses because it has not been known of for very long. Sepik virus was first isolated in 1966 from the mosquito Mansoniaseptempunctata, and it derives its name from the Sepik River area in Papua New Guinea, where it was first found. The geographic range of Sepik virus is limited to Papua New Guinea, due to its isolation.

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 "Rift Valley fever". Fact sheet N°207. World Health Organization. May 2010. Archived from the original on 15 April 2014. Retrieved 21 March 2014.
  2. Palmer SR (2011). Oxford textbook of zoonoses : biology, clinical practice, and public health control (2nd ed.). Oxford u.a.: Oxford Univ. Press. p. 423. ISBN   9780198570028. Archived from the original on 2017-09-08.
  3. 1 2 Rift Valley Fever Archived 2012-05-08 at the Wayback Machine reviewed and published by WikiVet, accessed 12 October 2011.
  4. Dessau M, Modis Y (January 2013). "Crystal structure of glycoprotein C from Rift Valley fever virus". Proceedings of the National Academy of Sciences of the United States of America. 110 (5): 1696–701. Bibcode:2013PNAS..110.1696D. doi: 10.1073/pnas.1217780110 . PMC   3562824 . PMID   23319635.
  5. "ViralZone: Phlebovirus". viralzone.expasy.org. Archived from the original on 2016-10-03. Retrieved 2016-09-14.
  6. Bird BH, Khristova ML, Rollin PE, Ksiazek TG, Nichol ST (2007-03-15). "Complete Genome Analysis of 33 Ecologically and Biologically Diverse Rift Valley Fever Virus Strains Reveals Widespread Virus Movement and Low Genetic Diversity due to Recent Common Ancestry". Journal of Virology. 81 (6): 2805–2816. doi:10.1128/JVI.02095-06. ISSN   0022-538X. PMC   1865992 . PMID   17192303.
  7. Jupp PG, Kemp A, Grobbelaar A, Lema P, Burt FJ, Alahmed AM, Al Mujalli D, Al Khamees M, Swanepoel R (September 2002). "The 2000 epidemic of Rift Valley fever in Saudi Arabia: mosquito vector studies". Medical and Veterinary Entomology. 16 (3): 245–52. doi: 10.1046/j.1365-2915.2002.00371.x . PMID   12243225.
  8. Turell MJ, Presley SM, Gad AM, Cope SE, Dohm DJ, Morrill JC, Arthur RR (February 1996). "Vector competence of Egyptian mosquitoes for Rift Valley fever virus". The American Journal of Tropical Medicine and Hygiene. 54 (2): 136–39. doi:10.4269/ajtmh.1996.54.136. PMID   8619436.
  9. Turell MJ, Lee JS, Richardson JH, Sang RC, Kioko EN, Agawo MO, Pecor J, O'Guinn ML (December 2007). "Vector competence of Kenyan Culex zombaensis and Culex quinquefasciatus mosquitoes for Rift Valley fever virus". Journal of the American Mosquito Control Association. 23 (4): 378–82. doi:10.2987/5645.1. PMID   18240513. S2CID   36591701.
  10. Fontenille D, Traore-Lamizana M, Diallo M, Thonnon J, Digoutte JP, Zeller HG (1998). "New vectors of Rift Valley fever in West Africa". Emerging Infectious Diseases. 4 (2): 289–93. doi:10.3201/eid0402.980218. PMC   2640145 . PMID   9621201.
  11. Swanepoel R, Coetzer JA (2004). "Rift Valley fever". In Coetzer JA, Tustin RC (eds.). Infectious diseases of livestock (2nd ed.). Cape Town: Oxford University Press Southern Africa. pp. 1037–70. ISBN   978-0195761702.
  12. Boiro I, Konstaninov OK, Numerov AD (1987). "[Isolation of Rift Valley fever virus from bats in the Republic of Guinea]". Bulletin de la Société de Pathologie Exotique et de Ses Filiales (in French). 80 (1): 62–67. PMID   3607999.
  13. 1 2 3 4 5 6 7 Boshra H, Lorenzo G, Busquets N, Brun A (July 2011). "Rift valley fever: recent insights into pathogenesis and prevention". Journal of Virology. 85 (13): 6098–105. doi:10.1128/JVI.02641-10. PMC   3126526 . PMID   21450816.
  14. Fensterl V, Sen GC (2009-01-01). "Interferons and viral infections". BioFactors. 35 (1): 14–20. doi:10.1002/biof.6. PMID   19319841. S2CID   27209861.
  15. 1 2 3 4 Ikegami T, Makino S (May 2011). "The pathogenesis of Rift Valley fever". Viruses. 3 (5): 493–519. doi: 10.3390/v3050493 . PMC   3111045 . PMID   21666766.
  16. Fields BN, Knipe DM, Howley PM (2013). Fields Virology, 6th Edition. Philadelphia, PA: Wolters Kluwer, Lippincott Williams & Wilkins. p. 441. ISBN   978-1-4511-0563-6.
  17. "Kemri develops kit for rapid test of viral disease". Archived from the original on 2016-09-06. Retrieved 2016-09-14.
  18. 1 2 3 4 "Prevention: Rift Valley Fever | CDC". US Centers for Disease Control and Prevention. Retrieved 24 September 2018.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  19. Fawzy M, Helmy YA (February 2019). "The One Health Approach is Necessary for the Control of Rift Valley Fever Infections in Egypt: A Comprehensive Review". Viruses. 11 (2): 139. doi: 10.3390/v11020139 . PMC   6410127 . PMID   30736362.
  20. Ikegami T, Hill TE, Smith JK, Zhang L, Juelich TL, Gong B, Slack OA, Ly HJ, Lokugamage N, Freiberg AN (July 2015). "Rift Valley Fever Virus MP-12 Vaccine Is Fully Attenuated by a Combination of Partial Attenuations in the S, M, and L Segments". Journal of Virology. 89 (14): 7262–76. doi:10.1128/JVI.00135-15. PMC   4473576 . PMID   25948740.
  21. Bird BH, Maartens LH, Campbell S, Erasmus BJ, Erickson BR, Dodd KA, Spiropoulou CF, Cannon D, Drew CP, Knust B, McElroy AK, Khristova ML, Albariño CG, Nichol ST (December 2011). "Rift Valley fever virus vaccine lacking the NSs and NSm genes is safe, nonteratogenic, and confers protection from viremia, pyrexia, and abortion following challenge in adult and pregnant sheep". Journal of Virology. 85 (24): 12901–09. doi:10.1128/JVI.06046-11. PMC   3233145 . PMID   21976656.
  22. Nanyingi MO, Munyua P, Kiama SG, Muchemi GM, Thumbi SM, Bitek AO, Bett B, Muriithi RM, Njenga MK (2015-07-31). "A systematic review of Rift Valley Fever epidemiology 1931–2014". Infection Ecology & Epidemiology. 5 (1): 28024. Bibcode:2015InfEE...528024N. doi:10.3402/iee.v5.28024. PMC   4522434 . PMID   26234531. Archived from the original on 2016-12-02.
  23. "Rift Valley Fever | CDC". www.cdc.gov. Archived from the original on 2016-12-04. Retrieved 2016-12-01.
  24. Daubney R, Hudson JR, Garnham PC (1931). "Enzootic hepatitis or rift valley fever. An undescribed virus disease of sheep cattle and man from east africa". The Journal of Pathology and Bacteriology. 34 (4): 545–79. doi:10.1002/path.1700340418.
  25. Murithi RM, Munyua P, Ithondeka PM, Macharia JM, Hightower A, Luman ET, Breiman RF, Njenga MK (March 2011). "Rift Valley fever in Kenya: history of epizootics and identification of vulnerable districts". Epidemiology and Infection. 139 (3): 372–80. doi: 10.1017/S0950268810001020 . PMID   20478084. S2CID   41617078.
  26. McMillen CM, Hartman AL (2018). "Rift Valley fever in animals and humans: Current perspectives". Antiviral Research. 156: 29–37. doi:10.1016/j.antiviral.2018.05.009. PMC   10316118 . PMID   29857007. S2CID   46918400.
  27. van Velden DJ, Meyer JD, Olivier J, Gear JH, McIntosh B (1977-06-11). "Rift Valley fever affecting humans in South Africa: a clinicopathological study". South African Medical Journal = Suid-Afrikaanse Tydskrif vir Geneeskunde. 51 (24): 867–71. PMID   561445.
  28. Arzt J, White WR, Thomsen BV, Brown CC (January 2010). "Agricultural diseases on the move early in the third millennium". Veterinary Pathology. 47 (1): 15–27. doi:10.1177/0300985809354350. PMID   20080480. S2CID   31753926.
  29. Bird BH, Ksiazek TG, Nichol ST, Maclachlan NJ (April 2009). "Rift Valley fever virus". Journal of the American Veterinary Medical Association. 234 (7): 883–93. doi:10.2460/javma.234.7.883. PMID   19335238. S2CID   16239209.
  30. "At least 75 people die of Rift Valley Fever in Kenya". International Herald Tribune. 7 January 2007. Archived from the original on 9 January 2007.
  31. "Deadly fever spreads Kenya Panic". BBC. 26 January 2007. Archived from the original on 1 May 2008.
  32. ProMED-mail Archived 2011-07-28 at the Wayback Machine . ProMED-mail. Retrieved on 2014-05-12.
  33. "Rift Valley fever in South Africa". WHO. Archived from the original on 2010-04-12.
  34. "Outbreak Summaries | Rift Valley Fever | CDC". 2019-02-15.
  35. "Rift Valley fever – Kenya". WHO. 18 June 2018. Archived from the original on June 23, 2018. Retrieved 1 July 2018.
  36. "Rift Valley Fever – Mayotte (France)". WHO. 13 May 2019. Archived from the original on July 1, 2019. Retrieved 15 May 2019.
  37. "Rift Valley fever – Kenya". World Health Organization. 12 February 2021. Archived from the original on February 12, 2021. Retrieved 24 February 2021.
  38. "Chemical and Biological Weapons: Possession and Programs Past and Present", James Martin Center for Nonproliferation Studies, Middlebury College, April 9, 2002, accessed November 14, 2008.
  39. "Select Agents and Toxins" (PDF). USDA-APHIS and CDC: National Select Agent Registry. 2011-09-19. Archived from the original (PDF) on 2012-02-25.
  40. Kieny M. "After Ebola, a Blueprint Emerges to Jump-Start R&D". Scientific American Blog Network. Archived from the original on 20 December 2016. Retrieved 13 December 2016.
  41. "List of Pathogens". World Health Organization. Archived from the original on 20 December 2016. Retrieved 13 December 2016.